Viveve Medical, Inc. Reports Net Loss of $20.6 Million for the Nine Months Ended September 30, 2022

Viveve Medical, Inc.(VIVE), a medical technology compan y specializing in women's health, has released its unaudited financial statements for the nine months ended September 30, 2022. The company reported a net loss of $20.6 million during this period. However, Viveve Medical also achieved significant revenue growth, with total revenue reaching $5.1 million.

Net Loss Reflects Challenges and Investments

Viveve Medical's financial statements revealed a net loss of $20.6 million for the nine months ended September 30, 2022. This loss reflects the company's ongoing challenges in the competitive healthcare industry, as well as its strategic investments in research and development. The net loss was primarily driven by operating expenses, including research and development costs of $5.9 million and selling, general, and administrative expenses of $10.5 million.

Revenue Growth Demonstrates Market Potential